WARREN, N.J., March 13, 2026 (Globe Newswire) — Tevogen (“Tevogen Bio Holdings Inc.” or the “Company”) (Nasdaq: TVGN) today announced performance improvements to its artificial intelligence platform operated through Tevogen.AI.
Tevogen.AI was built to solve a critical challenge in drug development: identifying the biological targets most likely to benefit patients before entering costly clinical trials.
Over the past year, the company has built a proprietary database of more than 655 million peptide sequences derived from approximately 24 million proteins. This represents nearly 16 billion data points across multiple disease areas. This database is continuously enriched using analysis of 37 million scientific publications.
Improving prediction accuracy
In a recent beta test of the PredicTcell™ model, Tevogen reported:
- Recall improved from 87% to 92% (model is finding more good targets)
- Accuracy increased from 40% to 48% (less inaccurate predictions)
- Improved overall accuracy score
- Increase in true positives and decrease in missed targets
- Significantly increased training sample size
These results allow for improved models that identify which immune targets are likely to be successful. The current version, trained on 1.8 million data points, is nearly 20 times more robust than the initial model, reflecting rapid scale and learning acceleration.
Today’s drug development relies heavily on trial and error, and by improving target prediction prior to clinical trials, Tevogen aims to:
- Reduce time to market
- Reduce development costs
- Increase the probability of clinical success
- Increase the value of patent-protected products
This development is based on an international patent application (WO 2025/129197) published by Tevogen.AI, which outlines a novel machine learning system for predicting immunologically active peptides, a key step in the development of targeted therapies for cancer and infectious diseases.
Production AI agents and continuous learning
Tevogen.AI currently operates three production AI agents:
- Continuous evaluation of 14 active peptide candidates
- Monitor newly published scientific literature
- Integrate wet lab results into AI systems
This creates a continuous learning loop between AI predictions and biological validation to enhance future performance.
Next steps and partnership strategy
As prediction accuracy continues to improve, Tevogen intends to explore partnerships with pharmaceutical companies to advance the production and development of selected peptide candidates.
Mittul Mehta, CIO and Head of Tevogen.AI, said, “Our goal is to reduce trial and error in immunotherapy design and ultimately predict the proteome for any combination of proteins and HLA types. As the quality of predictions improves, we believe we can meaningfully increase success rates while reducing development risk. That combination has the potential to create significant value over the long term.”
About Tevogen
Tevogen is a socially integrated healthcare company built on the principles of affordability, efficiency and scientific rigor. The company leverages artificial intelligence and precision T-cell therapy platforms, a patient-first, cost-disciplined operating model, and collaborations with global technology leaders to support the development of advanced life-saving treatments across multiple therapeutic areas and scalable solutions for the broader health system.
The company’s flagship initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of single-HLA-restricted, genetically unmodified, allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology and neurology, and its programs are built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, reducing failure rates, and supporting optimized clinical trial design through proprietary predictive technology. The platform leverages cloud and data services from leading technology providers such as Microsoft and Databricks to advance the long-term goal of predicting the proteome of specific protein and HLA combinations, enabling rapid and cost-effective treatment discovery.
Tevogen is exploring future strategic initiatives including domestic generic drugs, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to drive sustainable innovation and expand patient access through faster, more efficient and more equitable care models.
Forward-looking statements
This press release contains certain forward-looking statements, including, without limitation, statements relating to: POTENTIAL TRANSACTIONS AND POTENTIAL ADVANTAGES OF TRANSACTIONS. plans for Tevogen’s research and manufacturing capabilities; Expectations for future growth. Expectations for the Healthcare and Biopharmaceutical Industry. the development of Tevogen’s product candidates for the treatment of infectious diseases and cancer, their potential benefits and patient access; Forward-looking statements may be identified by words such as “may,” “might,” “will,” “expect,” “anticipate,” “could,” “potential,” “goal,” “opportunity,” “anticipate,” “believe,” “future” or similar words or expressions, or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors, including known and unknown risks, delays, uncertainties and other factors beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: the risk that the transaction may not be completed on favorable terms or at all; the risk that the expected benefits of a transaction may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including the competitive environment, technological advances and regulatory changes; changes in general economic conditions domestically and worldwide; the risk that Tevogen may be unable to implement its growth strategies or may have difficulty managing growth or expanding its operations; the risk that Tevogen may be unable to develop and maintain effective internal controls; failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities; These opportunities may be affected by, among other things, competition, Tevogen’s ability to grow economically and manage growth, and hire and retain key employees. the risk that Tevogen may not be able to keep pace with rapid technological developments to offer new and innovative products and services or make significant investments in new products and services that are not successful; Tevogen’s need to raise additional capital to fully realize its business plans; risks related to our ability to develop, license and obtain new treatments; the risk of regulatory litigation or proceedings relating to Tevogen’s business; uncertainties associated with the conduct, cost and completion of preclinical studies and clinical trials; risks associated with regulatory review, approval and commercial development; risks related to intellectual property protection; Tevogen’s operating history is limited. These factors are discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date on which they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
contact address
Tevogen Bio Communications
Phone number: 1 877 TEVOGEN, extension 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e46645d4-7bf3-4cb6-91d3-cb7ede5a0064.
